RTA COC vials were supplemented with diluted insulin (NovoRapid®, NovoNordisk) at 1 IU/mL, which was adapted for neonatal administration in cases of postnatal hyperglycaemia and hyperkalaemia.96,97 The vial in question is constructed from COC material, which is specifically designed for extended contact with drug solutions and offers low susceptibility to CCI-related issues. The gene discussed is INS; the disease is Hyperkalemia.